CFDE Data Portal | Search ARFGEF1-DT

	Label	Description
	ARFGEF1-DT Gene (Entity type)	ENSG00000271966 - ARFGEF1 divergent transcript
	GSE109285 3 V 2 GLUCAGON MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE116810 5 V 1 SELINEXOR HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE93156 idelalisib B cell 1 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE146982 metformin 4 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE172016 paclitaxel 2 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE238116 EGR1 HCC overexpression MHCC97-H PLC-PRF-5 3 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE176008 8 V 1 AZACITIDINE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE115542 digoxin 2 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE172219 adenosine 2 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS

ARFGEF1-DT

ENSG00000271966 - ARFGEF1 divergent transcript

GSE109285 3 V 2 GLUCAGON MOUSE UP

A Gene Set from LINCS

GSE116810 5 V 1 SELINEXOR HUMAN UP

A Gene Set from LINCS

GSE93156 idelalisib B cell 1 v 0 human dn

A Gene Set from LINCS

GSE146982 metformin 4 v 2 human up

A Gene Set from LINCS

GSE172016 paclitaxel 2 v 1 human up

A Gene Set from LINCS

GSE238116 EGR1 HCC overexpression MHCC97-H PLC-PRF-5 3 v 0 human up

A Gene Set from LINCS

GSE176008 8 V 1 AZACITIDINE HUMAN DN

A Gene Set from LINCS

GSE115542 digoxin 2 v 0 human up

A Gene Set from LINCS

GSE172219 adenosine 2 v 1 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.